Available until 10/1/2024
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
featured
Reports of Cutaneous T-Cell Lymphoma After Dupilumab Use
TAKE-HOME MESSAGE
- This pharmacovigilance study used data from the FDA Adverse Event Reporting System to assess the reports on cutaneous T-cell lymphoma (CTCL) after dupilumab use. Dupilumab showed the highest reporting odds ratio for CTCL compared with other biologics, including adalimumab, secukinumab, ustekinumab, and infliximab. In addition, there were no observed increases in reporting odds ratio signals with dupilumab for non-CTCL lymphomas or skin cancers. Notably, CTCL was not reported among patients taking dupilumab for non-skin conditions.
- This study showed that dupilumab was associated with a substantially higher reporting odds ratio for CTCL compared with other biologics used in dermatology; however, CTCL was not reported in patients taking dupilumab for non-skin conditions.
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersDupilumab, a mAb targeting the IL-4Rα subunit, emerged in 2017 as a promising intervention for atopic dermatitis (AD). Three clinical trials led to dupilumab's approval; no patients were diagnosed with lymphoma or cutaneous lymphoma during these trials. However, an increasing number of case reports have described biopsy-proven cutaneous T-cell lymphoma (CTCL) diagnosis or exacerbation after dupilumab initiation.
Additional Info
Journal of Investigative Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
J Invest Dermatol 2024 Jun 28;[EPub Ahead of Print], L Lavin, S Dusza, S GellerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.